SIX1 is overexpressed in various human cancers, including liver cancer, and its overexpression correlates with poor clinical outcomes.[12, 13, 14, 15] miR‐145‐5p is downregulated in many cancers, such as hepatocellular carcinoma, prostate cancer, breast cancer, and ovarian cancer,[36, 37, 38, 39] and low miR‐145‐5p expression is associated with poor prognosis in patients with liver cancer.[36] However, the clinical significance of DGUOK‐AS1 expression in liver cancer is unknown. Here, SIX1 is linked to ovarian cancer.